Breast cancerIndividualized selection of chemotherapy regimens based on the molecular characteristics of the cancer would be desirable. However, it is not currently feasible. The development of clinically useful predictors of response to chemotherapy has proven to be difficult. Recently, novel analytical ...
The most effective combination regimens at present contain doxorubicin. Pharmacologic studies at the cellular level can be expected to provide more effective combinations. The most effective way to combine hormonal and chemotherapeutic treatments is not known. In receptor positive women without life-...
Chemotherapyis a standard treatment for some types ofbreast cancer. The goal of chemotherapy, or chemo, is to improve overall survival. In some cases, however, it may be prescribed to simply provide comfort care by preventing the tumor from getting too large and causing discomfort. Whether your...
Question Is scalp cooling associated with a lower risk of hair loss when used by women receiving common adjuvant chemotherapy regimens for early-stage breast cancer? Findings In this multicenter study, hair loss of 50% or less (Dean score of 0-2) was seen in 66.3% of patients in the scalp...
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early Breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. The Lancet. 2012;379(9814):432–44. Article Google Scholar Bines J, Kestel...
identifying beneficial treatment regimens for BC patients that take advantage of IO therapies remains a challenge. Checkpoint inhibitors targeting the programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1) are clinically validated21and form the foundation for IO combination strategies, where ...
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA. February 5th 2025 A Patient-Centered Approach to Plastic Surgery Reconstruction Surviv...
In the long term, the NUS team hopes their discovery will enable scientists to better optimize magnetic regimens for more effective killing ofcancer cells, and in turn, translate this knowledge into effective therapies to benefit cancer patients. ...
The outcome for 758 consecutive patients who had received one or more chemotherapy regimens for recurrent or metastatic breast cancer is presented. The response rate following first line treatment was 34%. Median duration of response was 7.8 months, median time to progression was 3.7 months and med...
Moderate differences in efficacy between adjuvant chemotherapy regimens for breast cancer are plausible, and could affect treatment choices. We sought any such differences. Methods We undertook individual-patient-data meta-analyses of the randomised trials comparing: any taxane-plus-anthracycline-based regim...